Medication Development in Alcoholism: Investigating Glucocorticoid Antagonists

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2014 by The Scripps Research Institute
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Barbara J. Mason, The Scripps Research Institute
ClinicalTrials.gov Identifier:
NCT01548417
First received: March 5, 2012
Last updated: January 30, 2014
Last verified: January 2014
  Purpose

The primary hypotheses under test are that alcohol dependent subjects treated with mifepristone will report decreased craving for alcohol following cue- and stress induced exposure in the laboratory and report fewer symptoms of protracted abstinence (e.g., craving, anxiety, mood and sleep disturbances) under naturalistic conditions, significantly more than those treated with placebo.


Condition Intervention Phase
Alcoholism
Drug: Korlym (mifepristone)
Drug: Sugar Pill
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Official Title: Medication Development in Alcoholism: Investigating Glucocorticoid Antagonists

Resource links provided by NLM:


Further study details as provided by The Scripps Research Institute:

Primary Outcome Measures:
  • Craving to Drink [ Time Frame: 1 week ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Drinking [ Time Frame: 5 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 50
Study Start Date: March 2012
Estimated Study Completion Date: July 2016
Estimated Primary Completion Date: July 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Korlym (mifepristone) Drug: Korlym (mifepristone)
600 mg/day, oral pill, 7 days
Other Names:
  • Mifepristone
  • C-1073
  • Mifeprex
  • RU-486
Placebo Comparator: Sugar Pill Drug: Sugar Pill
600 mg/day, oral pill, 7 days

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female volunteers, 18-65 years of age
  • Meets DSM-IV criteria for current alcohol dependence
  • Subjects will not be seeking treatment because the medication studies are not treatment trials
  • Subjects must be abstinent a minimum of 3 days (but not more than 7 days) prior to the human lab session
  • Negative BAC and a CIWA score of < 8 at screening and time of lab session to eliminate acute alcohol or withdrawal effects on dependent measures
  • Subjects must be able to complete and understand questionnaires and study procedures in English and sign an informed consent

Exclusion Criteria:

  • Significant medical disorders that will increase potential risk or interfere with study participation as determined by the Study Physician
  • Female subjects with childbearing potential who are pregnant, nursing, or refuse to use double barrier (non-hormonal) methods of birth control for the duration of the study and one month thereafter
  • Meets DSM-IV criteria for a major Axis I disorder including mood or anxiety disorders or substance dependence disorders other than alcohol or nicotine dependence
  • History of allergy or hypersensitivity to the study drugs or the ingredients
  • Treatment within the month prior to screening with 1.) an investigational drug or vaccine; 2.) drugs that may influence study outcomes, e.g., disulfiram (Antabuse), naltrexone (ReVia), acamprosate (Campral), anticonvulsants, antidepressants.
  • In need of or currently taking any psychoactive medications.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01548417

Contacts
Contact: David Estey, B.A. 858-784-7331 destey@scripps.edu
Contact: Susan B. Quello, B.S. 858-784-7327 squello@scripps.edu

Locations
United States, California
The Scripps Research Institute Recruiting
La Jolla, California, United States, 92037
Contact: Susan B Quello, B.S.    858-784-7327    squello@scripps.edu   
Principal Investigator: Barbara J Mason, Ph.D.         
Sponsors and Collaborators
The Scripps Research Institute
Investigators
Principal Investigator: Barbara J Mason, PhD The Scripps Research Institute
  More Information

Additional Information:
No publications provided

Responsible Party: Barbara J. Mason, PI, The Scripps Research Institute
ClinicalTrials.gov Identifier: NCT01548417     History of Changes
Other Study ID Numbers: AA012602-11A1, 2R01AA012602-11A1
Study First Received: March 5, 2012
Last Updated: January 30, 2014
Health Authority: United States: Federal Government
United States: Food and Drug Administration
United States: Institutional Review Board

Keywords provided by The Scripps Research Institute:
Alcohol
Relapse

Additional relevant MeSH terms:
Alcoholism
Alcohol-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Glucocorticoids
Mifepristone
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Pharmacologic Actions
Abortifacient Agents, Steroidal
Abortifacient Agents
Reproductive Control Agents
Therapeutic Uses
Contraceptives, Oral, Synthetic
Contraceptives, Oral
Contraceptive Agents, Female
Contraceptive Agents
Contraceptives, Postcoital, Synthetic
Contraceptives, Postcoital
Hormone Antagonists
Luteolytic Agents
Menstruation-Inducing Agents

ClinicalTrials.gov processed this record on July 31, 2014